Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

New Live Attenuated Influenza A/England/42/72 (H3N2) Vaccine (Alice): Reactogenicity, Immunogenicity, and Protection Efficacy

Michael W. Rytel, Leon J. Jackson, Julian E. Ferstenfeld and Mari Ann Rosenkranz
The Journal of Infectious Diseases
Vol. 132, No. 6 (Dec., 1975), pp. 652-659
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30105950
Page Count: 8
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
New Live Attenuated Influenza A/England/42/72 (H3N2) Vaccine (Alice): Reactogenicity, Immunogenicity, and Protection Efficacy
Preview not available

Abstract

The Alice strain of influenza A/England/42/72 (H3N2) live attenuated vaccine, when given by the intranasal route to 133 volunteers, was relatively nonreactogenic; only 12% of the vaccinees had upper respiratory tract symptoms after immunization. Seroconversion in 87.2% of subjects whose titers of humoral hemagglutination-inhibiting antibody before immunization were <1:8 demonstrated the immunogenicity of the vaccine. The overall seroconversion rate was 66.1% (geometric mean titer of hemagglutination-inhibiting antibody, 1:40.9). Antibody levels were unchanged at six months in 95.5% and at 12 months in 91.7% of the vaccinees. Because of the lack of natural influenza A infection during the season monitored, an experimental challenge study with homotypic virus (influenza A/Udorn/307/72 [H3N2]) was conducted eight months after immunization of a sample population of 22 subjects. Twelve of these subjects were vaccinees whose titers of hemagglutination-inhibiting antibody were ≥1:64, and 10 were unimmunized controls whose titers of hemagglutination-inhibiting antibody were ≤1:8. The group with titers of ≥1:64 represented 40.2% of the immunized population. The vaccine was highly effective in this selected group, with a 91% protection efficacy against illness and a 100% rate of protection against illness associated with influenza A infection.

Page Thumbnails

  • Thumbnail: Page 
652
    652
  • Thumbnail: Page 
653
    653
  • Thumbnail: Page 
654
    654
  • Thumbnail: Page 
655
    655
  • Thumbnail: Page 
656
    656
  • Thumbnail: Page 
657
    657
  • Thumbnail: Page 
658
    658
  • Thumbnail: Page 
659
    659